Press Release – Adipopharma

press releases

Towards a New Drug Class in the Treatment of Type 2 Diabetes

July 20, 2025

Diabète de type 2 : cibler la résistance à l’insuline plutôt que l’hyperglycémie

July 19, 2025

To treat insulin resistance

July 19, 2022

당뇨 치료 신세계 시작? 인슐린 저항성 표적 최초 후보물질 'PATAS'

July 19, 2022

Diabète de type 2 : cibler la résistance à l’insuline plutôt que l’hyperglycémie

July 19, 2022

Vers une nouvelle classe de médicament pour traiter le diabète de type 2

July 18, 2022

Diabetes：一种治疗2型糖尿病的新药

July 15, 2022

Adipopharma’s First-in-class Candidate – PATAS – Shows Improvement in Whole-body Insulin Resistance and Associated Comorbidities in Vivo

July 15, 2022

Other news to note for July 14, 2022

July 14, 2022

AdipoPharma SAS – Headquarters
Nextmed, Bâtiment eXplora (Bureau A203)1907
2 rue Marie Hamm
67000 Strasbourg
France

AdipoPharma SRL
Biopark Gosselies
Belgique

AdipoPharma LLC
US Office Pittsburgh
Pennsylvania, USA

© 2025 AdipoPharma - Privacy Policy | Legal Notice | Management Of The Information Collected